Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nordiazepam (also known as nordazepam) is a long-acting 1,4-benzodiazepine derivative that functions as a partial agonist at the GABA-A receptor. It is primarily utilized for its anxiolytic, anticonvulsant, sedative, and muscle relaxant properties, specifically in the management of anxiety disorders. A defining characteristic of nordiazepam is its role as a major active metabolite for several widely used benzodiazepines, such as diazepam, chlordiazepoxide, and clorazepate. Due to its extremely long elimination half-life, which ranges from 36 to 200 hours, it can accumulate in the body with repeated dosing. Compared to other benzodiazepines, it is reported to have lower potency regarding amnesic and muscle-relaxing effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nordazepam.